Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1296-3151 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with T2DM | Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Semaglutide | Drug | Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Haemoglobin A1c (HbA1c) level | Measured in Percentage (%). | From baseline (3 months prior to or on the index date) to 6 months |
| Change in HbA1c level | Measured in millimoles per mol (mmol/mol) | From baseline (3 months prior to or on the index date) to 6 months |
| Proportion of participants achieving HbA1c less than (<) 7.0% | Measured in percentage of participants. | At 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in HbA1c level | Measured in %. | From baseline (3 months prior to or on the index date) to 12 months |
| Change in HbA1c level | Measured in mmol/mol. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants diagnosed with T2DM who initiated semaglutide OW for the first time during the patient identification period.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 2834) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tianjin Medical University Chu Hsien-I Memorial Hospital | Tianjin | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41848818 | Derived | Wang S, Hu P, Shen Z, Chen L. Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. Diabetes Ther. 2026 Apr;17(4):587-602. doi: 10.1007/s13300-026-01848-6. Epub 2026 Mar 18. |
Not provided
Not provided
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000591245 | semaglutide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From baseline (3 months prior to or on the index date) to 12 months |
| Proportion of participants achieving HbA1c <7.0% | Measured in percentage of participants. | At 12 months |
| Change in body weight | Measured in kilograms. | From baseline (3 months prior to or on the index date) to 12 months |
| Change in body weight | Measured in kilograms. | From baseline (3 months prior to or on the index date) to 6 months |
| Description of participants with different demographic characteristics | At baseline (12 months prior to or on the index date) |
| Description of participants with different clinical characteristics | At baseline (36 months prior to or on the index date) |
| Proportion of participants with different antidiabetic medications | Measured in percentage of participants. | At baseline (3 months prior to or on the index date) |
| Proportion of participants with different non-antidiabetic medications | Measured in percentage of participants. | At baseline (3 months prior to or on the index date) |
| D004700 | Endocrine System Diseases |